Glycyrrhizic acid (Synonyms: 甘草酸; Glycyrrhizin)

目录号: HY-N0184 纯度: 99.84%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

溶解度

动物溶解方案

实验小贴士

Glycyrrhizic acid 是甘草里面的活性成分三萜皂苷，为 HMGB1 的拮抗剂，有用于肿瘤、糖尿病等研究的潜力。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Glycyrrhizic acid Chemical Structure

CAS No. : 1405-86-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
50 mg	￥500	In-stock
100 mg	￥700	In-stock
500 mg	￥2100	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Glycyrrhizic acid:

MCE 顾客使用本产品发表的 30 篇科研文献

: Glycyrrhizic acid purchased from MCE. Usage Cited in: Cell Prolif. 2020 Jun;53(6):e12829. [Abstract]; Protein levels of pro-caspase-1 + p10 + p12, GADMD, IL-1β, IL-18 and NLRP3 are detected by Western blotting. Glycyrrhizin inhibits pyroptosis in TNF-α-induced M1 macrophages.

Glycyrrhizic acid 相关产品

•相关化合物库:

•同靶点产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Glycyrrhizic acid is a triterpenoid saponinl, acting as a direct HMGB1 antagonist, with anti-tumor, anti-diabetic activities.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
ECV-304	IC₅₀	> 119 μM Compound: Glycyrrhizinic acid	Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay	[PMID: 24084294]
ECV-304	IC₅₀	> 238 μM Compound: Glycyrrhizinic acid	Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay	[PMID: 24084294]
HEK293	IC₅₀	0.015 μM Compound: glycyrrhizic acid	Inhibition of mouse liver microsome 11betaHSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay Inhibition of mouse liver microsome 11betaHSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay	[PMID: 19574056]
HEK293	IC₅₀	0.4 nM Compound: glycyrrhizinic acid	Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay	[PMID: 22360639]
HEK293	IC₅₀	0.7 nM Compound: glycyrrhizinic acid	Inhibition of human 11beta-HSD2 expressed in human HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay Inhibition of human 11beta-HSD2 expressed in human HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay	[PMID: 22148241]
HEK293	EC₅₀	1 nM Compound: Glycyrrhizic acid	Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as [3H]cortisol production after 60 mins by SPA Inhibition of human 11beta-HSD2 expressed in HEK293 cells assessed as [3H]cortisol production after 60 mins by SPA	[PMID: 22440625]
HEK293	IC₅₀	1 nM Compound: glycyrrhizic acid	Inhibition of human microsomal 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay Inhibition of human microsomal 11beta-HSD2 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay	[PMID: 19564108]
HEK293	EC₅₀	10 nM Compound: Glycyrrhizic acid	Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as [3H]cortisol production after 60 mins by SPA Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as [3H]cortisol production after 60 mins by SPA	[PMID: 22440625]
HEK293	IC₅₀	10 nM Compound: glycyrrhizic acid	Inhibition of human microsomal 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay Inhibition of human microsomal 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay	[PMID: 19564108]
HEK293	IC₅₀	18.6 nM Compound: glycyrrhizinic acid	Inhibition of human 11beta-HSD1 expressed in human HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay Inhibition of human 11beta-HSD1 expressed in human HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay	[PMID: 22148241]
HEK293	IC₅₀	29.5 nM Compound: glycyrrhizinic acid	Inhibition of mouse 11beta-HSD1 expressed in human HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay Inhibition of mouse 11beta-HSD1 expressed in human HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay	[PMID: 22148241]
HEK293	IC₅₀	3 nM Compound: glycyrrhizinic acid	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay	[PMID: 22360639]
HEK293	IC₅₀	6 nM Compound: glycyrrhizinic acid	Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay Inhibition of human 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone into [3H]cortisol by scintillation proximity assay	[PMID: 22360639]
HEK293	EC₅₀	8 nM Compound: Glycyrrhizic acid	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as [3H]cortisol production after 60 mins by SPA Inhibition of mouse 11beta-HSD1 expressed in HEK293 cells assessed as [3H]cortisol production after 60 mins by SPA	[PMID: 22440625]
HEK293	IC₅₀	8 nM Compound: glycyrrhizic acid	Inhibition of mouse microsomal 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay Inhibition of mouse microsomal 11beta-HSD1 expressed in HEK293 cells assessed as conversion of [3H]cortisone to [3H]cortisol by scintillation proximity assay	[PMID: 19564108]
Hepatocyte	IC₅₀	> 200 μM Compound: glycyrrizhin	Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay	[PMID: 11277757]
Hepatocyte	IC₅₀	82.4 μM Compound: glycyrrhizin	Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs	[PMID: 11325227]
MDCK	EC₅₀	15.2 μM Compound: 15	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25801933]
MDCK	EC₅₀	364.6 μM Compound: 1, GL	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25801933]
MDCK	IC₅₀	39.6 μM Compound: 112	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in dog MDCK cells preincubated with virus for 15 mins followed by cells addition measured at 36 hrs post infection Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in dog MDCK cells preincubated with virus for 15 mins followed by cells addition measured at 36 hrs post infection	[PMID: 26841168]
Raji	IC₅₀	381 μM Compound: 8	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48hrs by indirect immunofluorescence technique Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48hrs by indirect immunofluorescence technique	[PMID: 19131254]
RAW264.7	ED₅₀	70 μM Compound: 1, GL	Inhibition of HMGB1 in mouse RAW264.7 cells assessed as LPS-induced TNFalpha release treated for 2 hrs prior to LPS-challenge measured after 16 hrs by ELISA Inhibition of HMGB1 in mouse RAW264.7 cells assessed as LPS-induced TNFalpha release treated for 2 hrs prior to LPS-challenge measured after 16 hrs by ELISA	[PMID: 23199028]
Vero C1008	CC₅₀	> 100 μM Compound: 1; GL	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in survival rate measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in survival rate measured after 48 hrs by MTT assay	[PMID: 31519375]

体外研究
(In Vitro)

Glycyrrhizic acid 显示出一系列抗癌相关的药理活性，如广谱抗癌能力、抵抗化疗和放疗引起的组织毒性、药物吸收促进作用和抗多药耐药 (MDR) 机制，作为药物输送系统中的载体材料^[1]。
在分泌GLP-1的肠道NCI-H716细胞中，Glycyrrhizic acid 促进GLP-1分泌，钙水平显著升高。Glycyrrhizic acid 可通过激活TGR5促进GLP-1分泌^[2]。
Glycyrrhizic acid 可在 37°C 下形成稳定透明的低分子量水凝胶 (LMWHs) 以纳米团簇为微观结构的生理磷酸盐缓冲液 (PBS)^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

在链脲佐菌素诱导的 1 型糖尿病大鼠 (STZ 处理的大鼠) 中，Glycyrrhizic acid 增加血浆 GLP-1 的水平，而氨苯蝶啶在足以抑制 Takeda G 蛋白偶联受体 5 (TGR5) 的剂量下被阻断^[1]。
Glycyrrhizic acid (Glycyrrhizic acid；50 mg/kg，ip) 显著降低小鼠体内 TgAb、HMGB1、TNF-α、IL-6、IL-1β 的水平^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04028869	Beijing Ditan Hospital	Autoimmune Liver Disease	March 1, 2018
NCT05925309	Children´s Hospital of Fudan University	Biliary Atresia\|Cholangitis\|Anti-Bacterial Agents	June 28, 2023	Not Applicable
NCT04742660	Konkuk University Medical Center	Postoperative Nausea	May 11, 2021	Not Applicable
NCT05276895	Assiut University	Osteoarthritis	July 1, 2022	Not Applicable
NCT05788705	Adel A.Gomaa\|Assiut University	Rheumatoid Arthritis	July 2023	Not Applicable

分子量

822.93

Formula

C₄₂H₆₂O₁₆

CAS 号

1405-86-3

性状

固体

颜色

White to off-white

中文名称

甘草酸；甘草皂甙；甘草甜素；强力宁；甘草皂苷

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (121.52 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2152 mL	6.0759 mL	12.1517 mL
5 mM	0.2430 mL	1.2152 mL	2.4303 mL
10 mM	0.1215 mL	0.6076 mL	1.2152 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.04 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.04 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.04 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

扫码获得
动物溶解方案

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO， PEG300/PEG400，Tween 80，均可在 MCE 网站选购。

纯度 & 产品资料

纯度： 99.84%

选择批次：

Data Sheet (655 KB) SDS (393 KB)

COA (294 KB)HNMR (329 KB)RP-HPLC (268 KB)LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Su X, et al. Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 2017 Sep 5;95:670-678 [Content Brief]

[2]. Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Sep 4;95:599-604. [Content Brief]

[3]. Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731. [Content Brief]

[4]. Xia Zhao, et al. A Simple Injectable Moldable Hydrogel Assembled from Natural Glycyrrhizic Acid with Inherent Antibacterial Activity. ACS Appl. Bio Mater. 2020, 3, 1, 648–653.

Animal Administration ^[3]	Mice^[3] NOD.H-2^h4 mice are fed in the animal house until 4 weeks of age. A total of 24 male mice are then randomly separated into three different groups (n=8 per group). Mice in the control group are given sterile water without supplement. Mice in the iodine supplement (NaI) group are given 0.005% NaI in the drinking water. Mice in the NaI+Glycyrrhizic acid group are treated with 50 mg/kg Glycyrrhizic acid once daily for 4 weeks, administered via intraperitoneal injection after 8 weeks of iodine supplementation. Thyroid tissues are removed surgically under anesthesia, washed with cold saline, blotted on filter paper and weighed using an electronic balance. The thyroid gland tissues are then stored at -80°C until use^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Su X, et al. Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 2017 Sep 5;95:670-678 [Content Brief] [2]. Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Sep 4;95:599-604. [Content Brief] [3]. Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731. [Content Brief] [4]. Xia Zhao, et al. A Simple Injectable Moldable Hydrogel Assembled from Natural Glycyrrhizic Acid with Inherent Antibacterial Activity. ACS Appl. Bio Mater. 2020, 3, 1, 648–653.

Animal Administration
^[3]

Mice^[3]
NOD.H-2^h4 mice are fed in the animal house until 4 weeks of age. A total of 24 male mice are then randomly separated into three different groups (n=8 per group). Mice in the control group are given sterile water without supplement. Mice in the iodine supplement (NaI) group are given 0.005% NaI in the drinking water. Mice in the NaI+Glycyrrhizic acid group are treated with 50 mg/kg Glycyrrhizic acid once daily for 4 weeks, administered via intraperitoneal injection after 8 weeks of iodine supplementation. Thyroid tissues are removed surgically under anesthesia, washed with cold saline, blotted on filter paper and weighed using an electronic balance. The thyroid gland tissues are then stored at -80°C until use^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Su X, et al. Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 2017 Sep 5;95:670-678 [Content Brief]

[2]. Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Sep 4;95:599-604. [Content Brief]

[3]. Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731. [Content Brief]

[4]. Xia Zhao, et al. A Simple Injectable Moldable Hydrogel Assembled from Natural Glycyrrhizic Acid with Inherent Antibacterial Activity. ACS Appl. Bio Mater. 2020, 3, 1, 648–653.

Glycyrrhizic acid 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2152 mL	6.0759 mL	12.1517 mL	30.3793 mL
	5 mM	0.2430 mL	1.2152 mL	2.4303 mL	6.0759 mL
	10 mM	0.1215 mL	0.6076 mL	1.2152 mL	3.0379 mL
	15 mM	0.0810 mL	0.4051 mL	0.8101 mL	2.0253 mL
	20 mM	0.0608 mL	0.3038 mL	0.6076 mL	1.5190 mL
	25 mM	0.0486 mL	0.2430 mL	0.4861 mL	1.2152 mL
	30 mM	0.0405 mL	0.2025 mL	0.4051 mL	1.0126 mL
	40 mM	0.0304 mL	0.1519 mL	0.3038 mL	0.7595 mL
	50 mM	0.0243 mL	0.1215 mL	0.2430 mL	0.6076 mL
	60 mM	0.0203 mL	0.1013 mL	0.2025 mL	0.5063 mL
	80 mM	0.0152 mL	0.0759 mL	0.1519 mL	0.3797 mL
	100 mM	0.0122 mL	0.0608 mL	0.1215 mL	0.3038 mL

Help & FAQs

HY-N0184, HY-N0184A 的区别是什么呢？
HY-N0184, HY-N0184A 的生物活性是等效的，其中 HY-N0184 是游离态，HY-N0184A 是盐形式，溶解度会有差异。

Keywords:

Glycyrrhizic acid1405-86-3Glycyrrhizin甘草酸甘草皂甙甘草甜素强力宁甘草皂苷Virus ProteaseInhibitorinhibitorinhibit

您最近查看的产品:

Glycyrrhizic acid

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Glycyrrhizic acid (Synonyms: 甘草酸; Glycyrrhizin)

Customer Review

Other Forms of Glycyrrhizic acid:

Glycyrrhizic acid 相关抗体

MCE 顾客使用本产品发表的 30 篇科研文献

Glycyrrhizic acid 相关产品

•相关化合物库:

•同靶点产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Glycyrrhizic acid 相关抗体:

摩尔计算器

稀释计算器

Glycyrrhizic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z